Dongmei Ji

机构：Shanghai Medical College of Fudan University, Anhui Medical University, Shanghai University of Electric Power, Fudan University, Fudan University Shanghai Cancer Center, First Affiliated Hospital of Anhui Medical University · ORCID：0000-0003-0647-0153

发表论文 278 篇 · 总被引 2167 次 · h-index 20

代表论文

• A Phase II study of SHR-A1921, a TROP2-targeted antibody–drug conjugate, in patients with recurrent or metastatic salivary gland carcinoma (2026 · npj Precision Oncology · 被引 1)
• Multiparametric quantitative MRI combining SyMRI and MUSE-DWI for noninvasive stratification of HER2 status in breast cancer (2025 · Frontiers in Oncology · 被引 1)
• Biomarker-Stratified Phase II Trial of Trastuzumab Rezetecan in Advanced Salivary Gland Carcinoma Across Cohorts With High and Low Human Epidermal Growth Factor Receptor 2 Expression (2026 · Journal of Clinical Oncology)
• Supplementary Table S8 from LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial (2026)
• Supplementary Figure S1 from LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial (2026)
• Supplementary Table S6 from LM-101, an Anti-SIRPα Antibody, in Patients with Relapsed/Refractory Lymphoma and Advanced Head and Neck Cancer: An Open-Label, Multicenter, Phase I Trial (2026)